Publications by authors named "Marie-Anne Vandenhende"
Exposure to COVID-19 Pandemic-Related Stressors and Their Association With Distress, Psychological Growth and Drug Use in People With HIV in Nouvelle Aquitaine, France (ANRS CO3 AQUIVIH-NA Cohort-QuAliV-QuAliCOV Study).
AIDS Behav
January 2025
We investigated people living with HIV (PLWH)'s exposure to COVID-19 pandemic stressors and their association with distress, psychological growth, and substance use. PLWH in the ANRS CO3 AQUIVIH-NA cohort's QuAliV study (Nouvelle Aquitaine, France) completed an adapted CAIR Lab Pandemic Impact Questionnaire (C-PIQ) and reported substance use between 9/2021 to 3/2022. We described cumulative stressor exposure (score 0-16) and explored variation by PLWH characteristics (demographic, HIV-related, risk factors, psychosocial).
View Article and Find Full Text PDFArticle Synopsis
- This study examines central catheter-related bloodstream infections (CRBIs) at a tertiary care hospital over two years, focusing on complications caused by various bacteria, particularly Staphylococcus aureus (SA).
- Among 254 patients, 14% experienced complications such as suppurative thrombophlebitis and endocarditis, with risk factors including prolonged bacteremia, hemodialysis, and infections by SA.
- The findings suggest that patients with persistent bacteremia, especially those with SA and on hemodialysis, require thorough monitoring for potential complications to improve outcomes.
Background: Severe non-AIDS bacterial infections (SBIs) are among the leading causes of hospital admissions among persons with human immunodeficiency virus (PWH) in regions with high antiretroviral therapy coverage.
Methods: This large prospective cohort study of PWH examined the types of infections, bacterial documentation, and evolution of antibiotic resistance among PWH hospitalized with SBIs over an 18-year period.
Results: Between 2000 and 2017, 459 PWH had at least 1 SBI with bacterial documentation.
Introduction: Hearing loss is a rare manifestation in giant cell arteritis. The different types of deafness are possible with a predominance of sensorineural deafness.
Case Report: We report a 75-year-old woman who presented with typical manifestations of giant cell arteritis associated concomitantly with the occurrence of bilateral mixed hearing loss confirmed on the audiogram.
Article Synopsis
- Bacterial infections are a significant health issue for individuals living with HIV (PLHIV), and although statins have shown protective effects in other groups, their impact on PLHIV is still debated.
- This study aimed to assess whether statin usage reduces the chances of experiencing a first severe bacterial infection (SBI) in a large cohort of PLHIV from 2000 to 2018.
- The results indicated that statins did not significantly affect the incidence of SBIs or pneumonia among PLHIV over the 18-year follow-up period, suggesting that statins may not offer the protective benefits seen in other populations.
Background: Combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir has been suggested as an approach to improve the outcome of patients with moderate/severe COVID-19 infection.
Objectives: To examine the safety of combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir.
Methods: This was an observational cohort study of patients hospitalized for COVID-19 pneumonia treated with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir.
Whipple's disease usually presents as chronic joint pain followed by digestive manifestations. However, many different presentations have been described in the literature. We report here the first proven case of muscular vasculitis related to Whipple's disease, associated with an expansion of circulating activated γδ T lymphocytes.
View Article and Find Full Text PDFBackground: The differential effects of commonly prescribed combined antiretroviral therapy (cART) regimens on AIDS-defining neurological conditions (neuroAIDS) remain unknown.
Setting: Prospective cohort studies of HIV-positive individuals from Europe and the Americas included in the HIV-CAUSAL Collaboration.
Methods: Individuals who initiated a first-line cART regimen in 2004 or later containing a nucleoside reverse transcriptase inhibitor backbone and either atazanavir, lopinavir, darunavir, or efavirenz were followed from cART initiation until death, lost to follow-up, pregnancy, the cohort-specific administrative end of follow-up, or the event of interest, whichever occurred earliest.
We describe the effect of interleukin 6 (IL-6) blockade using tocilizumab (TCZ) for inducing and maintaining remission of refractory polyarteritis nodosa (PAN). Three patients with refractory PAN defined according to the American College of Rheumatology criteria were treated with TCZ infusions (8 mg/kg) on a monthly basis. All of them had severe cutaneous and articular involvement with elevated biological inflammatory markers.
View Article and Find Full Text PDFBackground: Clinical guidelines recommend immediate initiation of combined antiretroviral therapy for all HIV-positive individuals. However, those guidelines are based on trials of relatively young participants.
Methods: We included HIV-positive antiretroviral therapy-naive, AIDS-free individuals aged 50-70 years after 2004 in the HIV-CAUSAL Collaboration.
Objective: To compare regimens consisting of either ritonavir-boosted atazanavir or efavirenz and a nucleoside reverse transcriptase inhibitor (NRTI) backbone with respect to clinical, immunologic, and virologic outcomes.
Design: Prospective studies of human immunodeficiency virus (HIV)-infected individuals in Europe and the United States included in the HIV-CAUSAL Collaboration.
Methods: HIV-positive, antiretroviral therapy-naive, and acquired immune deficiency syndrome (AIDS)-free individuals were followed from the time they started an atazanavir or efavirenz regimen.
Severe non-AIDS bacterial infections (SBI) are the leading cause of hospital admissions among people living with HIV (PLHIV) in industrialized countries. We aimed to estimate the incidence of SBI and their risk factors in a large prospective cohort of PLHIV patients over a 13-year period in France. Patients followed up in the ANRS CO3 Aquitaine cohort between 2000 and 2012 were eligible; SBI was defined as a clinical diagnosis associated with hospitalization of ≥48 hours or death.
View Article and Find Full Text PDFArticle Synopsis
- The text talks about when to change treatments in people with HIV, comparing two different strategies: one that reacts quickly (tight-control) and one that is more relaxed (loose-control).
- Researchers studied real-life data to see how these two strategies affected survival and health outcomes in patients.
- The results showed that there were slightly more deaths and health issues in the loose-control group, but the numbers were small, so more research is needed to draw strong conclusions.
Objectives: We studied the link between T-cell activation, differentiation and senescence phenotypes and non-AIDS-related comorbidities in HIV-suppressed patients.
Design: Patients included in the ANRS CO3 Aquitaine Cohort were consecutively enrolled in this cross-sectional study between October 2011 and May 2013 called Chronic Immune Activation and Senescence (CIADIS) study.
Methods: We summarized immune markers [CD4 and CD8 activation (DR), differentiation (naive and terminally differentiated memory T cells), and senescence (CD57CD28)] in a weighted immune score by principal component analysis called CIADIS.
Background: The goal of this work was to assess the safety and efficacy of biologics (ie, tumor necrosis factor-α antagonists and tocilizumab) in patients with Takayasu arteritis.
Methods And Results: This was a retrospective, multicenter study of the characteristics and outcomes of 49 patients with Takayasu arteritis (80% female; median age, 42 years [20-55 years] treated by tumor necrosis factor-α antagonists [80%] or tocilizumab [20%]) and fulfilling American College of Rheumatology or Ishikawa criteria. Factors associated with complete response were assessed.
Article Synopsis
- * The study showed a significant increase in non-AIDS/non-hepatitis-related cancers, with respiratory cancers, particularly lung cancer, becoming the leading cause of death among these patients.
- * Researchers emphasized the need for improved cancer prevention and treatment strategies, especially for respiratory cancers, to reduce mortality in HIV-infected individuals.
Background: We assessed the association of persistent low-level viraemia between 50-199 copies/ml (LLV) with the risk of virological failure (VF) among HIV-1-infected patients receiving combination antiretroviral therapy (ART).
Methods: ART-naive and ART-experienced patients followed up in the ANRS-CO3 Aquitaine Cohort were included if they started two nucleoside reverse transcriptase inhibitors (NRTIs) with either one non-nucleoside reverse transcriptase inhibitor (NNRTI) or one protease inhibitor boosted with ritonavir (PI/r) between 2000 and 2011 and achieved viral load (VL)<200 copies/ml 4-8 months after initiating ART. VF was defined as either two consecutive VL≥200 copies/ml or one VL≥200 followed by a modification of ART.
Background: The goal of antiretroviral therapy (ART) is to reduce HIV-related morbidity and mortality by suppressing HIV replication. The prognostic value of persistent low-level viremia (LLV), particularly for clinical outcomes, is unknown.
Objective: Assess the association of different levels of LLV with virological failure, AIDS event, and death among HIV-infected patients receiving combination ART.
Background: Current clinical guidelines consider regimens consisting of either ritonavir-boosted atazanavir or ritonavir-boosted lopinavir and a nucleoside reverse transcriptase inhibitor (NRTI) backbone among their recommended and alternative first-line antiretroviral regimens. However, these guidelines are based on limited evidence from randomized clinical trials and clinical experience.
Methods: We compared these regimens with respect to clinical, immunologic, and virologic outcomes using data from prospective studies of human immunodeficiency virus (HIV)-infected individuals in Europe and the United States in the HIV-CAUSAL Collaboration, 2004-2013.
There are no data on how to manage implantable intra-arterial catheter (IAC) infections. We report the case of a patient with liver metastases of colon cancer treated by regional intra-arterial chemotherapy who presented a suspected IAC-related infection, in whom daptomycin systemic treatment and lock therapy allowed to cure the IAC infection.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the prevalence of low-frequency drug resistance mutations (DRMs) in HIV-1 patients before and after starting antiretroviral therapy (ART) who experienced virological failure (VF).
- Twenty-nine patients from a cohort started ART between 2000 and 2009 were analyzed using Ultra-Deep Sequencing (UDS) and Sanger sequencing to identify DRMs.
- Results showed that UDS detected significantly more low-frequency DRMs, which altered predictions of resistance to treatments, with some mutations only becoming prevalent at VF.
Article Synopsis
- - Genotypic resistance testing is crucial for determining if HIV can resist certain antiretroviral drugs, but traditional methods can miss low-frequency viral variants.
- - The study evaluated ultradeep pyrosequencing (UDPS) on HIV-1 samples from 47 treatment-naive patients to assess its effectiveness for clinical resistance testing at Bordeaux University Hospital.
- - Results showed that 8.5% of patients had only low-frequency resistance mutations, and 19.1% had mutations associated with rilpivirine resistance, indicating that UDPS could be a valuable routine tool in clinical settings.
Background/purpose: The aim of this study is to analyze the efficacy and tolerance of tocilizumab in patients with Takayasu arteritis (TA).
Methods: We retrospectively studied patients with TA (ACR and/or Ishikawa's criteria): 5 French multicenter cases and 39 from the literature. Clinical, biological, radiological disease activity and treatment were analyzed before tocilizumab, during the follow-up and at the last available visit.
Objective: To examine the role of antiretroviral drugs (ART), HIV-related and traditional risk factors on the incidence of chronic kidney disease (CKD) in HIV-infected patients.
Design: Prospective hospital-based cohort of HIV-infected patients from 2004 to 2012.
Methods: CKD was defined using MDRD equation as an estimated glomerular filtration rate (eGFR) less than 60 ml/mn/1.